Roclatan | Beye

Compare IOP Reduction

15 products »

Home > Ophthalmic Drugs > IOP Reduction

Coming Soon

Roclatan

Aerie Pharmaceuticals, Inc

Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% is a fixed-dose combination of Rhopressa and latanoprost, a prostaglandin analog. The once-daily eyedrop is intended to reduce intraocular pressure in patients with glaucoma or ocular hypertension.

TOP

Description

Related Products

Details

In The News

Company

At-a-Glance

Mechanism of Action: Netarsudil is a rho kinase inhibitor, which is believed to reduce IOP by increasing the outflow of aqueous humor through the trabecular meshwork route. Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow.
Dosage: This medication is still under investigation but the recommended dosage will likely be one drop once daily in the evening.

Details

FDA

Under investigation

CE Mark

Not specified

Active Ingredients

Netarsudil/Latanoprost

Application

Topical

Status

Prescription

Strength

0.02%/0.005%

In the News

Aerie Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update »

Eyewire | 08.09.18

Aerie Pharmaceuticals Announces Early Notification of FDA Acceptance of NDA Submission for Roclatan »

Eyewire | 07.23.18

Aerie Pharmaceuticals Announces Early Notification of FDA Acceptance of NDA Submission for Roclatan »

Eyewire | 07.23.18

Show More

Company Information

Contact the company for additional information, availability, or pricing:

Aerie Pharmaceuticals, Inc

aeriepharma.com

info@aeriepharma.com

4301 Emperor Blvd

Durham, NC 27703

Compare IOP Reduction »

15 products »

View All IOP Reduction »

15 products »

Privacy | Terms & Conditions Ⓒ 2024 Beye, LLC. All rights reserved.

This content is intended for health care professionals and providers only. The information contained on Beye.com, including text, graphics, images, and interactive activities, is for informational purposes only, and is not intended to be a substitute for professional medical advice. Beye LLC, via its Editors and Publisher, accepts no responsibility for any injury or damage to persons or property occasioned through the implementation of any ideas or use of any product described herein. Although great care is taken to ensure that all information is accurate, it is recommended that readers seek independent verification of advice on drugs and other product usage, surgical techniques and clinical processes prior to their use. References made in article may indicate usage of medical equipment or drugs at dosages, for periods of time, and in combination not included in the current prescribing information. Inclusion of advertising materials on the website thereof, does not constitute and representation or guarantee by Beye LLC of the quality of such products, or of the claims made.